US 10,376,505 B2
Oral formulations and lipophilic salts of methylnaltrexone
Syed M. Shah, Delray Beach, FL (US); Christopher Richard Diorio, Campbell Hall, NY (US); Eric C. Ehrnsperger, New City, NY (US); Xu Meng, San Diego, CA (US); Kadum A. Al Shareffi, Greensboro, NC (US); and Jonathan Marc Cohen, Monroe, NY (US)
Assigned to Wyeth, LLC, Madison, NJ (US)
Filed by Wyeth, LLC, Madison, NJ (US)
Filed on Dec. 13, 2018, as Appl. No. 16/219,159.
Application 16/219,159 is a continuation of application No. 15/070,555, filed on Mar. 15, 2016, abandoned.
Application 15/070,555 is a continuation of application No. 13/956,050, filed on Jul. 31, 2013, granted, now 9,314,461, issued on Apr. 19, 2016.
Application 13/956,050 is a continuation of application No. 13/045,108, filed on Mar. 10, 2011, granted, now 8,524,276, issued on Sep. 3, 2013.
Claims priority of provisional application 61/313,018, filed on Mar. 11, 2010.
Prior Publication US 2019/0117645 A1, Apr. 25, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/485 (2006.01); A61K 9/20 (2006.01); C07D 489/08 (2006.01); A61K 9/28 (2006.01); A61K 47/12 (2006.01); A61K 47/20 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/485 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2054 (2013.01); A61K 9/2077 (2013.01); A61K 9/28 (2013.01); A61K 47/12 (2013.01); A61K 47/20 (2013.01); C07D 489/08 (2013.01)] 30 Claims
 
1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion, based upon the total weight of the composition.